Kyprolis

Carfilzomib, the active ingredient in Kyprolis, is a proteasome inhibitor presented as an intravenous solution for intravenous use. It is indicated for the treatment of relapsed or refractory multiple myeloma in adult patients who have received prior therapy.

GNH USA supplies Kyprolis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kyprolis (carfilzomib) is used in the management of plasma cell malignancies, specifically multiple myeloma.

Multiple myeloma (relapsed or refractory): Improves disease control and prolongs progression‑free survival in patients who have received prior treatment. Multiple myeloma (post‑autologous stem cell transplant): Provides maintenance therapy to extend remission after transplant. Multiple myeloma (combination therapy): Used with dexamethasone and/or lenalidomide to enhance overall response rates.

Kyprolis may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Anemia: reduced red blood cell count leading to weakness. - Thrombocytopenia: lowered platelet count increasing bleeding risk.

Serious or Rare Side Effects: - Cardiac toxicity: heart failure or reduced ejection fraction. - Pulmonary hypertension: elevated pressure in lung arteries. - Severe infusion reactions: hypotension, dyspnea, or anaphylaxis. - Renal failure: acute kidney injury requiring monitoring.

Before initiating Kyprolis, clinicians should assess several safety parameters.

Cardiac monitoring: evaluate baseline cardiac function and watch for signs of heart failure. Hematologic monitoring: perform regular complete blood counts to detect anemia, neutropenia or thrombocytopenia. Infection risk: monitor for febrile neutropenia and treat infections promptly. Liver function: check hepatic enzymes before and during therapy. Pregnancy and lactation: avoid use; safety not established and contraception is advised. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kyprolis can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly decrease carfilzomib levels. - Concurrent proteasome inhibitors: risk of additive toxicity. - Anticoagulants (e.g., warfarin): increased bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise carfilzomib exposure. - Drugs that prolong QT interval: monitor ECG for arrhythmias. - Nephrotoxic agents (e.g., cisplatin): observe renal function closely.